Journal of psychosocial nursing and mental health servicesHumansLorazepamNurse PractitionersDelayed-Action PreparationsUnited States
Exploration of Extended-Release Lorazepam: Implications for Safe Nurse Practitioner Practice.
Karan Kverno, Pamela J Biernacki
Published: 202610.3928/02793695-20251208-02
Abstract
In 2021, the U.S. Food and Drug Administration approved Loreev XR®, a long-acting formulation of lorazepam, raising important clinical considerations for nurse practitioners (NPs) who routinely manage anxiety, insomnia, and stress-related conditions.…
Preview only. Read the full abstract at the source